MAPMI Extended-Spectrum Pathogenic Microorganism mNGS Detection

Name: MAPMI Extended-Spectrum Pathogenic Microorganism mNGS Detection
Brand: CapitalBio Technology Co., Ltd.

Next-generation sequencing metagenomic sequencing is the basis for CapitalBio®MAPMI detection, which allows for the direct detection of nucleic acid in a sample, the acquisition of sequencing information for any present microorganisms in the sample, and the unbiased identification of any pathogens that may be present.

Inquire Now

Features of MAPMI Extended-Spectrum Pathogenic Microorganism mNGS Detection

1. Detection of 16109 viruses, 13362 bacteria, 1659 fungi, 270 parasites, and 2500 drug resistance genes

2.

Targets	Sensitivity
virus	1000 copies/mL
Bacteria, fungi, and parasites	100 copies/mL

3. Target population

Patients who fall into this category have been identified as immunosuppressed hosts, patients with underlying disorders, and patients with severe infections who have been hospitalized multiple times.
Patients who repeatedly fail standard microbiological tests and have subpar therapy responses
Patients who are clinically suspected of harboring emerging diseases and who show signs of becoming infectious
Individuals who may be infected with a certain virus
Patients with additional clinical signs and prolonged fever and/or infection of unknown etiology
MAPMI Test is also available in CapitalBio Medical Lab